Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032693 | 0.89 | HTR1A (0.51) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL6844238 | 0.89 | HTR1A (0.64) | HTR1ASLC6A4DRD2HTR6 | |
| SCHEMBL6848226 | 0.89 | HTR1A (0.64) | HTR1ASLC6A4DRD2DRD4DRD3 | |
| SCHEMBL6847481 | 0.88 | HTR1A (0.78) | HTR1ASLC6A4DRD2HTR6HTR2A | |
| SCHEMBL6627255 | 0.86 | HTR1A (0.63) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL6844182 | 0.85 | HTR1A (0.66) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL5843529 | 0.81 | HTR1A (0.60) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6843636 | 0.81 | HTR1A (0.60) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL27512557 | 0.81 | HTR1A (0.49) | HTR1ASLC6A4DRD2CYP3A4CYP2C8 | |
| SCHEMBL7034985 | 0.80 | HTR1A (0.53) | HTR1ASLC6A4DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392700-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALENE | WYETH CORP (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1392700-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALENE | Wyeth (US) | 2004-03-03 | — | — | EP | claimed |
| US-6525075-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-02-25 | — | — | US | claimed |
| US-20020183354-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | claimed |
| WO-2002088140-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1392700-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALENE | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1392700-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALENE | Wyeth (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6617334-B2 | Inhibiting the reuptake of serotonin in a subject suffering from postraumatic stress, ADD, premenstrual dysphoria, obesity, eating disorder, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction | WYETH | 2003-09-09 | — | — | US | disclosed |
| US-6613913-B2 | Intermediate for antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta [a]naphthalene | WYETH | 2003-09-02 | — | — | US | disclosed |
| US-20030134871-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | WYETH | 2003-07-17 | — | — | US | disclosed |
| US-20030109562-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH | 2003-06-12 | — | — | US | disclosed |
| US-6525075-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020183354-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088140-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109562-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta[a]naphthalene | OPRD1, HTR1A, HTR1D | HTR1A 2/4885SLC6A4 88/4885DRD2 20/4885 |
| US-20020183354-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | OPRD1, HTR1A, HTR1D | HTR1A 2/4885SLC6A4 88/4885DRD2 20/4885 |
| US-20030134871-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | OPRD1, HTR1A, HTR1D | HTR1A 2/4885SLC6A4 88/4885DRD2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.